Zhejiang Medicine Co., Ltd. Class A

Zhejiang Medicine Co., Ltd. Class A

SSSE:600216
10.54
CNY
0.00
(0.00%)
0.46EPS
18.77P/E
11.95BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A carries a market capitalization of 11.95B, placing it among publicly traded companies globally. Its enterprise value stands at 9.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.95B
Enterprise Value9.51B

Important Dates

Zhejiang Medicine Co., Ltd. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A has 961.64M shares outstanding.

Shares Outstanding961.64M

Valuation Ratios

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 18.77. The price-to-sales ratio is 1.41, and the price-to-book ratio stands at 1.04.

PE Ratio18.77
PS Ratio1.41
PB Ratio1.04
P/TBV Ratio1.10

Enterprise Valuation

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A trades at an EV/EBITDA multiple of 16.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.51B versus a market cap of 11.95B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.13
EV / EBITDA16.05
EV / EBIT16.05

Financial Position

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A maintains a current ratio of 3.59, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.84, indicating elevated leverage, while an interest coverage ratio of 25.64 demonstrates strong ability to service its debt obligations.

Current Ratio3.59
Quick Ratio1.71
Debt / Equity7.84
Debt / EBITDA1.57
Interest Coverage25.64

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.56M in revenue per employee across its workforce of 5,417.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.56M
Employee Count5,417.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Medicine Co., Ltd. Class A recorded 127.37M in income tax expense. That works out to an effective tax rate of 22.29, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 571.44M, leaving 633.03M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax127.37M
Effective Tax Rate22.29

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Medicine Co., Ltd. Class A's stock has declined approximately 27.06% over the past 52 weeks. The 50-day moving average sits at 11.94, while the 200-day moving average is 13.47.

52-Week Price Change-27.06%
50-Day Moving Average11.94
200-Day Moving Average13.47

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Medicine Co., Ltd. Class A generated 8.43B in revenue and converted that into 633.03M in net income, yielding earnings per share of 0.46. EBITDA reached 592.35M, while operating income came in at 851.75M.

Revenue8.43B
Gross Profit2.77B
Operating Income851.75M
Pretax Income571.44M
Net Income633.03M
EBITDA592.35M
EBIT592.35M
Earnings Per Share (EPS)0.46

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A holds 3.77B in cash and equivalents against 931.41M in total debt, resulting in a net debt position of -2.44B. Total book value stands at 11.49B, with working capital of 5.70B providing operational flexibility.

Cash & Cash Equivalents3.77B
Total Debt931.41M
Net Debt-2.44B
Equity (Book Value)11.49B
Book Value Per Share11.95
Working Capital5.70B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-532.04M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Medicine Co., Ltd. Class A posted a gross margin of 32.85, reflecting its pricing power and cost economics. The operating margin of 10.10 and net profit margin of 7.51 provide insight into operational efficiency.

Gross Margin32.85
Operating Margin10.10
Pretax Margin6.78
Profit Margin7.51
EBITDA Margin7.03

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Medicine Co., Ltd. Class A paid dividends of 0.30 per share. The dividend payout ratio of 114.10 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.93, meaning Zhejiang Medicine Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.30
Payout Ratio114.10
Shareholder Yield-1.93

Stock Splits

Zhejiang Medicine Co., Ltd. Class A's most recent stock split took place on October 9, 2013 with a 5:9 split ratio.

Last Split Date10/9/2013
Split Ratio5:9

Scores

As of September 30, 2026, Zhejiang Medicine Co., Ltd. Class A has an Altman Z-Score of 4.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.46